US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Antares Pharma, Inc. - Common Stock (NQ:ATRS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Antares Pharma, Inc. - Common Stock

News headline image
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS
From Kuznicki Law PLLC
Via Business Wire
News headline image
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
From Kahn Swick & Foti, LLC
Via Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
News headline image
ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire